×

Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in Abiomed, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 15, 2013 Lead Plaintiff Deadline

STEVENSON, Md., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of the common stock of Abiomed, Inc. ("Abiomed" or the "Company") (NYSE:ABMD) during the period between August 5, 2011 and October 31, 2012, inclusive (the "Class Period").

If you have suffered a net loss for all transactions in Abiomed, Inc. common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than January 15, 2013 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period that the Company had not addressed and resolved the concerns of the United States Food and Drug Administration that the Company's promotional materials contained inappropriate claims regarding the Impella 2.5 catheter and suggested improper off-label uses. According to the complaint, following Abiomed's November 1, 2012 disclosure that the Department of Justice had initiated an investigation relating to the Company's marketing and labeling of the Impella 2.5., the value of Abiomed shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven Brower Piven, A Professional Corporation Stevenson, Maryland 410/415-6616 hoffman@browerpiven.comSource: Brower Piven, A Professional Corporation